[Advances in perioperative antiviral therapy for HBV/HCV-associated hepatocellular carcinoma].
Chronic viral hepatitis has a high prevalence rate in China, and the presence or absence of hepatitis virus replication is closely associated with the surgical outcome of patients. Therefore, perioperative antiviral therapy becomes an important method for improving patients' outcome. On the basis of treatment modalities and features of different viral infections, this article elaborates on the strategies and effects of perioperative antiviral therapy, in order to guide clinical practice and improve patients' prognosis.